Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX 470 vs latanoprost in open-angle glaucoma or ocular hypertension
CTR20211278Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NCX 470 in open-angle glaucoma (OAG), ocular hypertension, pigmentary glaucoma (PG), pseudoexfoliation glaucoma (PXG), sponsored by Nicox S.A.. Started Jun 2021; status: completed.
02
Drugs
NCX 470
03
Conditions
open-angle glaucoma (OAG)ocular hypertensionpigmentary glaucoma (PG)pseudoexfoliation glaucoma (PXG)
Beyond the preview
Go deeper on CTR20211278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211278.